Please use this identifier to cite or link to this item:
Title: Safety run-in results from phase 3 study of canakinumab (CAN) or placebo in combination with pembrolizumab (PEM) plus platinum based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC (CANOPY-1)
Authors: JOHNSON, Bruce E.KIM, Tae MinHILTERMANN, T. Jeroen N.BARLESI, FabriceGROHE, ChristianGOTO, YasushiGUNNARSSON, OrvarOVERBECK, TobiasREGUART, NoemiWERMKE, MartinCASTRO, GilbertoFELIP, EnriquetaGREYSTOKE, AlastairSOLOMON, Benjamin J.NEBOT, NoeliaDEUDON, StephanieLOUVEAU, Anne-LaurePASSOS, Vanessa Q.TAN, Daniel S. W.
Citation: MOLECULAR CANCER THERAPEUTICS, v.18, n.12, suppl.S, 2019
Appears in Collections:

Comunicações em Eventos - FM/MDR
Departamento de Radiologia - FM/MDR

Comunicações em Eventos - HC/ICESP
Instituto do Câncer do Estado de São Paulo - HC/ICESP

Comunicações em Eventos - LIM/24
LIM/24 - Laboratório de Oncologia Experimental

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.